Skip to main content
. 2020 May 26;11(21):1929–1941. doi: 10.18632/oncotarget.27586

Table 2. Treatment-related adverse events.

Toxicity-no. Total Arm A (N = 11) Arm B (N = 11)
Any Grade G3–4 Any Grade G3–4
Any event 17 6 - 11 3
Laboratory
platelet count decreased 6 6 1
anemia 2 2 1
neutrophil count decreased 2 2
elevated rapamycin level 2 2
alkaline phosphatase increased 1 1
hypokalemia 1 1 1
hyponatremia 1 1 1
Gastrointestinal
nausea/vomiting 6 3 3
diarrhea, loose stools 6 2 4
abdominal pain 3 3
bloating 3 2 1
anorexia 2 2
abdominal distension 1 1
early satiety 1 1
mucositis 1 1
Generalized
diaphoresis 4 2 2
chills 2 1 1
edema 2 2
fatigue 2 2
weight loss 2 2
fever 1 1
dehydration 1 1
Dermatologic
rash 4 4
dry skin 1 1
pruritis 1 1
Respiratory
cough 1 1
dyspnea 1 1
sore throat 1 1
upper respiratory infection 1 1
Other
arthralgia 2 2
paresthesia 1 1

*Events were counted once for each patient using the highest grading.